[{"orgOrder":0,"company":"Biostax","sponsor":"Immgenuity","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"IMTVO14","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biostax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Biostax \/ Biostax","highestDevelopmentStatusID":"4","companyTruncated":"Biostax \/ Biostax"}]

Find Clinical Drug Pipeline Developments & Deals by Biostax

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : The joint research will focus on using Immgenuity’s IMTV014 and Biostax’s Lodonal™ and JKB-122 both independently and together to determine if the immune modulatory effects of Biostax’s drug therapies combined with Immgenuity’s IMTV014 can achi...

                          Brand Name : IMTVO14

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          August 29, 2023

                          Lead Product(s) : IMTVO14,Naltrexone

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : Immgenuity

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank